Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-12-03
1998-02-17
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, 514179, A61K 3156
Patent
active
057191379
ABSTRACT:
A method of using a steroidal compound, 17.alpha.-dihydroequilenin, to prevent and treat neurodegeneration and cognitive dysfunction in estrogen deficient females and to reduce the risk of Alzheimer's related dementia and other senile dementia related conditions in both males and females. The method comprises administering 17.alpha.-dihydroequilenin in a therapeutically effective amount to a mammal in need of increased cognitive function or to a mammal susceptible to estrogen deficiency-related neurodegeneration or to senile dementia of the Alzheimer's type.
REFERENCES:
patent: 3507889 (1970-04-01), Marshall
patent: 4154820 (1979-05-01), Simoons
patent: 5510342 (1996-04-01), Washburn et al.
patent: 5545635 (1996-08-01), Bryant et al.
Effects of Estrogen On Memory Function In Surgically Menopausal Women; Psychoneuroendocrinology, vol. 17, No. 5, pp. 485-495, 1992.
Gonadal Steroids Regulate Dendritic Spine Density In Hippocampal Pyramidal Cells in Adulthood: The Journal Of Neuroscience, Apr. 1990. 10(4) : 1286-1291.
The Potential Role For Estrogen Replacement Therapy in the Treatment of the Congnitive Decline and Neurodegeneration Associated With Alzheimer's Disease Neurogiology of Aging, vol. 15, Suppl. 2, pp. S195-S197, 1994.
Premarin Intracenous, Physicians' Desk Reference, 1996 p. 2787.
The Saga of the Ring B Unsaturated Equine Estrogens Endocrine Reviews, 1988.
Hormone Therapy To Prevent Disease and Prolong Life in Posmenopausal Woman, Annals of Internal Medicine, vol. 117, No. 12, 15 Dec. 1992.
Association of Hormone-Replacement Therapy With Various Cardiovascular Risk Factors In Postmenopausal Women The Journal of New England Medicine, vol. 328, No. 15 Apr. 15, 1993, pp. 1069-1075.
Correlates of Postmenopausal Estrogen Use and Trends Through the 1980s in Two Southeastern New England Communities; American Journal of Epidemiology, vol. 137 No. 10, pp. 1125-1135, 1993.
Bleeding Patterns in Postmenopausal Women Taking Continuous combined or Sequential Regimens of Conjugated Estrogens With Medroxyprogesterone Adetate; Obstetrics & Gynecology, vol. 83, No. 5, Part 1, May 1994.
The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women; The N.E. Journal Of Medicine, vol. 332, No. 24, Jun. 15, 1995.
Reduced Mortality Associated With Long-Term Postmenpausal Estrogen Therapy; Obstetrics & Gynecology, vol. 87, No. 1 Jan. 1996.
A Conjugated Equine Estrogen with Differential Effects on Uterine Weight and Plasma Cholesterol in the Rat Am. J. Obstet. Gynecol; Aug. 1993, pp. 251-256.
Interaction of Ring B Unsaturated Estrogens with Estrogen Receptors of Human Endometrium and Rat Uterus Steroids, 1991, vol. 56, April pp. 201-210.
Premarin Components: Uterine, Cholesterol Lowering, and Bone Metabolic Effects, Jun. 1996 Endocrine Research, Lilly Research Laboratories.
Pharmacology of Conjugated Oestrogens; Elsener Bio-Medical Press, 1982 pp. 332-339.
Sex Hormones and Psychological Functioning in Post-Menopausal Women; Experimental Gerontology, vol. 29, Nos. 3/4, pp.423-430 1994.
Effects of 17.alpha.-Dihydroequilenin Sulfate on Athero-Sclerotic Male and Female Rhesus Monkeys; Am J. Obstet Gynecol; Aug.1996, pp. 341-351.
Roles of Estradiol and Progesterone in Regulation of Hippocampal Dendritic Spine Density During the Estrous Cycle in the Rat; Journal of Comparative Neurology, 1993.
Evaluation of Equilin 3-Monosulfate and Other Estrogens Arch Intern Med/vol. 128, Aug. 1971.
The Metabolism of Equilin in Normal Men; J.Steroid Bio-chem, vol. 17, pp. 217-23, 1982.
Pharmacokinetics of Equilin and Equilin Sulfate in Normal women and Men; J. Clinical Endo. and Meta., 1983 vol. 56, No.5 1048-1056.
Pharmacokinetics of 17.alpha.-Dihydroequilin Sulfate and 17.alpha.-Dihydroequilin in Normal Postmenopausal Women; Journal of Clinical Endocrinology and Metabolism, vol. 78 No. 1, pp.197-204, 1994.
Shively Carol Ann
Washburn Scott A.
Criares Theodore J.
Wake Forest University
LandOfFree
Method of preventing neurodegeneration and cognitive dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing neurodegeneration and cognitive dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing neurodegeneration and cognitive dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784103